within Pharmacolibrary.Drugs.ATC.C;

model C10AA04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.24,
    Cl             = 3e-05,
    adminDuration  = 600,
    adminMass      = 40 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.035,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.036833333333333336,
    Tlag           = 12.6
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C10AA04</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Fluvastatin is an orally administered lipid-lowering agent that belongs to the statin class of drugs. It is primarily used to reduce levels of cholesterol and triglycerides in the blood and is approved for the treatment of hypercholesterolemia and mixed dyslipidemia to prevent cardiovascular disease.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers after a single oral dose administration.</p><h4>References</h4><ol><li><p>Kosoglou, T, et al., &amp; Alton, KB (2005). Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. <i>Clinical pharmacokinetics</i> 44(5) 467–494. DOI:<a href=\"https://doi.org/10.2165/00003088-200544050-00002\">10.2165/00003088-200544050-00002</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/15871634/\">https://pubmed.ncbi.nlm.nih.gov/15871634</a></p></li><li><p>Scripture, CD, &amp; Pieper, JA (2001). Clinical pharmacokinetics of fluvastatin. <i>Clinical pharmacokinetics</i> 40(4) 263–281. DOI:<a href=\"https://doi.org/10.2165/00003088-200140040-00003\">10.2165/00003088-200140040-00003</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11368292/\">https://pubmed.ncbi.nlm.nih.gov/11368292</a></p></li><li><p>Lee, CK, et al., &amp; Bang, JS (2013). Effects of Fluvastatin on the Pharmacokinetics of Repaglinide: Possible Role of CYP3A4 and P-glycoprotein Inhibition by Fluvastatin. <i>The Korean journal of physiology &amp; pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology</i> 17(3) 245–251. DOI:<a href=\"https://doi.org/10.4196/kjpp.2013.17.3.245\">10.4196/kjpp.2013.17.3.245</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23776402/\">https://pubmed.ncbi.nlm.nih.gov/23776402</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C10AA04;
